Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiovascular Systems to expand US PAD (peripheral arterial disease) trial of atherectomy system:

This article was originally published in Clinica

Executive Summary

The US FDA has given Cardiovascular Systems the all clear to expand a clinical trial of its Orbital Atherectomy System (OAS) in the removal of plaque from peripheral arteries. The OASIS study is the first prospective, multicentre, clinical trial for an atherectomy device treating peripheral arterial disease (PAD), claims the St Paul, Minnesota firm; the first OASIS trial patient was enrolled in January 2006. OAS is a catheter-based system that uses a diamond-coated crown to remove plaque, creating a final lumen that is around twice the size of the crown. It is already approved in the US for treating occluded AV grafts used in haemodialysis access, and it is cleared in Europe for the peripheral vascular indication.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel